{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T12:17:43Z","timestamp":1762517863043,"version":"build-2065373602"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"European Union \u2013 Next Generation EU, National Institute for Research of Metabolic and Cardiovascular Diseases","award":["LX22NPO5104"],"award-info":[{"award-number":["LX22NPO5104"]}]},{"name":"Charles University, Czechia,  Research Program COOPERATIO \u2013 Cardiovascular Science"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Patients with acute myocardial infarction (AMI) who have concomitant peripheral artery disease (PAD) represent a subgroup at high risk of subsequent ischaemic events. This post hoc analysis of PRAGUE-18, a multicenter, randomised trial comparing prasugrel versus ticagrelor in primary PCI, analysed the effect of symptomatic PAD and intensity of antithrombotic therapy on the prognosis of AMI patients treated with primary percutaneous coronary intervention (PCI). During 12-month follow-up, de-escalation from intensive antiplatelet therapy to clopidogrel was allowed with the permission of the treating physician for economic reasons. Symptomatic PAD was present in 2.9% of the study population (n\u2009=\u20091230). The presence of PAD did not significantly affect short-term outcome. At one year, the risk of death was higher in patients with concomitant PAD, 49 (4.1%) vs. 6(16.7%), HR 4.211 (1.803\u20139.830); p\u2009=\u20090,001. All-cause mortality significantly increased only in subgroup of patients who de-escalated to clopidogrel [6.37 (2.16\u201318.84), p\u2009=\u20090.001] as opposed to those who did not [3.02 (0.72\u201312.61), p\u2009=\u20090.13]. These findings suggest that long-term intensive antithrombotic therapy may be particularly important for post-AMI patients with concomitant symptomatic PAD and warrant further investigation.<\/jats:p>","DOI":"10.1038\/s41598-025-24372-2","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T12:12:39Z","timestamp":1762517559000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intensive antithrombotic therapy is necessary for long-term treatment in patients with symptomatic peripheral artery disease after acute myocardial infarction"],"prefix":"10.1038","volume":"15","author":[{"given":"Jan","family":"Matejka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzana","family":"Motovska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ota","family":"Hlinomaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Kala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milan","family":"Hromadka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivo","family":"Varvarovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslav","family":"Dusek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiri","family":"Jarkovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Rokyta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Mrozek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Cervinka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislav","family":"Simek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiri","family":"Ostransky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"issue":"5","key":"24372_CR1","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJM199201303260506","volume":"326","author":"V Fuster","year":"1992","unstructured":"Fuster, V., Badimon, L., Badimon, J. J. & Chesebro, J. H. The pathogenesis of coronary artery disease and the acute coronary syndromes. N. Engl. J. Med. 326(5), 310\u2013318 (1992).","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"24372_CR2","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/heartjnl-2013-304517","volume":"100","author":"CP Gale","year":"2014","unstructured":"Gale, C. P. et al. Trends in hospital treatments, including revascularisation, following acute myocardial infarction, 2003\u20132010: A multilevel and relative survival analysis for the national institute for cardiovascular outcomes research (NICOR). Heart 100(7), 582\u2013589 (2014).","journal-title":"Heart"},{"issue":"20","key":"24372_CR3","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1016\/j.jacc.2014.08.037","volume":"64","author":"F Pedersen","year":"2014","unstructured":"Pedersen, F. et al. Short- and long-term cause of death in patients treated with primary PCI for STEMI. J. Am. Coll. Cardiol. 64(20), 2101\u20132108 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"38","key":"24372_CR4","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne, R. A. et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur. Heart J. 44(38), 3720\u20133826 (2023).","journal-title":"Eur. Heart J."},{"issue":"20","key":"24372_CR5","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott, S. D. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20), 2001\u20132015 (2007).","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"24372_CR6","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin, L. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045\u20131057 (2009).","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"24372_CR7","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jama.297.11.1197","volume":"297","author":"PG Steg","year":"2007","unstructured":"Steg, P. G. et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 297(11), 1197\u20131206 (2007).","journal-title":"JAMA"},{"issue":"9901","key":"24372_CR8","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","volume":"382","author":"FG Fowkes","year":"2013","unstructured":"Fowkes, F. G. et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: A systematic review and analysis. Lancet 382(9901), 1329\u20131340 (2013).","journal-title":"Lancet"},{"key":"24372_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.atherosclerosis.2022.01.007","volume":"344","author":"O Kobo","year":"2022","unstructured":"Kobo, O. et al. Impact of peripheral artery disease on prognosis after percutaneous coronary intervention: Outcomes from the multicenter prospective e-ULTIMASTER registry. Atherosclerosis 344, 71\u201377 (2022).","journal-title":"Atherosclerosis"},{"issue":"9","key":"24372_CR10","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1161\/CIRCRESAHA.116.303849","volume":"116","author":"MH Criqui","year":"2015","unstructured":"Criqui, M. H. & Aboyans, V. Epidemiology of peripheral artery disease. Circ. Res. 116(9), 1509\u20131526 (2015).","journal-title":"Circ. Res."},{"key":"24372_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.atherosclerosis.2022.05.002","volume":"355","author":"TH Pinxterhuis","year":"2022","unstructured":"Pinxterhuis, T. H. et al. Outcome after percutaneous coronary intervention with contemporary stents in patients with concomitant peripheral arterial disease: A patient-level pooled analysis of four randomized trials. Atherosclerosis 355, 52\u201359 (2022).","journal-title":"Atherosclerosis"},{"issue":"9","key":"24372_CR12","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"V Aboyans","year":"2018","unstructured":"Aboyans, V. et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the european society for vascular surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: The European stroke organization (ESO)the task force for the diagnosis and treatment of peripheral arterial diseases of the European society of cardiology (ESC) and of the European society for vascular surgery (ESVS). Eur. Heart J. 39(9), 763\u2013816 (2018).","journal-title":"Eur. Heart J."},{"issue":"23","key":"24372_CR13","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1016\/j.jacc.2016.03.524","volume":"67","author":"MP Bonaca","year":"2016","unstructured":"Bonaca, M. P. et al. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J. Am. Coll. Cardiol. 67(23), 2719\u20132728 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9038","key":"24372_CR14","first-page":"1329","volume":"348","author":"CAPRIE Steering Committee","year":"1996","unstructured":"CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 348(9038), 1329\u20131339 (1996).","journal-title":"CAPRIE Steering Committee. Lancet."},{"issue":"6","key":"24372_CR15","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1177\/2047487314533215","volume":"22","author":"MR Patel","year":"2015","unstructured":"Patel, M. R. et al. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. Eur. J. Prev. Cardiol. 22(6), 734\u2013742 (2015).","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"10117","key":"24372_CR16","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","volume":"391","author":"SS Anand","year":"2018","unstructured":"Anand, S. S. et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: An international, randomised, double-blind, placebo-controlled trial. Lancet 391(10117), 219\u2013229 (2018).","journal-title":"Lancet"},{"issue":"7","key":"24372_CR17","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1001\/jamacardio.2016.2811","volume":"1","author":"A Franzone","year":"2016","unstructured":"Franzone, A. et al. Prolonged vs short duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with or without peripheral arterial disease: A subgroup analysis of the PRODIGY randomized clinical trial. JAMA Cardiol. 1(7), 795\u2013803 (2016).","journal-title":"JAMA Cardiol."},{"issue":"21","key":"24372_CR18","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1161\/CIRCULATIONAHA.116.024823","volume":"134","author":"Z Motovska","year":"2016","unstructured":"Motovska, Z. et al. Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: multicenter randomized PRAGUE-18 study. Circulation 134(21), 1603\u20131612 (2016).","journal-title":"Circulation"},{"issue":"4","key":"24372_CR19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jacc.2017.11.008","volume":"71","author":"Z Motovska","year":"2018","unstructured":"Motovska, Z. et al. 1-year outcomes of patients undergoing primary angioplasty for myocardial infarction treated with prasugrel versus ticagrelor. J. Am. Coll. Cardiol. 71(4), 371\u2013381 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"23","key":"24372_CR20","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran, R. et al. Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the bleeding academic research consortium. Circulation 123(23), 2736\u20132747 (2011).","journal-title":"Circulation"},{"issue":"1","key":"24372_CR21","doi-asserted-by":"publisher","first-page":"e001004","DOI":"10.1136\/openhrt-2018-001004","volume":"6","author":"R Attar","year":"2019","unstructured":"Attar, R., Wester, A., Koul, S., Eggert, S. & Andell, P. Peripheral artery disease and outcomes in patients with acute myocardial infarction. Open Heart. 6(1), e001004 (2019).","journal-title":"Open Heart."},{"issue":"1","key":"24372_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1161\/CIRCULATIONAHA.120.046048","volume":"142","author":"J Steffel","year":"2020","unstructured":"Steffel, J. et al. The COMPASS trial: Net clinical benefit of low-dose rivaroxaban plus aspirin as compared with aspirin in patients with chronic vascular disease. Circulation 142(1), 40\u201348 (2020).","journal-title":"Circulation"},{"issue":"20","key":"24372_CR23","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","volume":"36","author":"DJ Angiolillo","year":"2017","unstructured":"Angiolillo, D. J. et al. International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies. Circulation 36(20), 1955\u20131975 (2017).","journal-title":"Circulation"},{"issue":"10104","key":"24372_CR24","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","volume":"390","author":"D Sibbing","year":"2017","unstructured":"Sibbing, D. et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): A randomised, open-label, multicentre trial. Lancet 390(10104), 1747\u20131757 (2017).","journal-title":"Lancet"},{"issue":"41","key":"24372_CR25","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1093\/eurheartj\/ehx175","volume":"38","author":"T Cuisset","year":"2017","unstructured":"Cuisset, T. et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur. Heart J. 38(41), 3070\u20133078 (2017).","journal-title":"Eur. Heart J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24372-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24372-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24372-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T12:12:40Z","timestamp":1762517560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24372-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["24372"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-24372-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"12 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39133"}}